Figure 4. Orlistat, enzalutamide and the combination of both decrease NF-κB activity determined with EMSA.

The cell culture conditions and drug treatments were as described in the legend of Figure 2. Both orlistat alone (ORL 35 and 80 µM) and enzalutamide alone (ENZ 35 and 100 µM) suppressed the activity of NF-κB in a dose-dependent manner. Combination treatment showed the most significant inhibition of NF-κB activity with relatively low doses. All experiments were repeated at least three times, while only one repeat was randomly selected for presentation.